A study commissioned by the National Football League reports that Alzheimer's disease or similar memory-related diseases appear to have been diagnosed in the league's former players vastly more often than in the national population - including a rate of 19 times the normal rate for men ages 30 through 49.
The N.F.L. has long denied the existence of reliable data about cognitive decline among its players. These numbers would become the league's first public affirmation of any connection, though the league pointed to limitations of this study.
Oleocanthal, a naturally-occuring compound found in extra-virgin olive oil, alters the structure of neurotoxic proteins believed to contribute to the debilitating effects of Alzheimer's disease. This structural change impedes the protein's ability to damage brain nerve cells.
"The findings may help identify effective preventative measures and lead to improved therapeutics in the fight against Alzheimer's disease," said study co-leader Paul A. S. Breslin, PhD, a sensory psychobiologist at the Monell Center.
A new study published in the medical journal Neurology suggests that impaired kidney function is a risk factor for cognitive decline in old age. The study, conducted by researchers at Rush University Medical Center, found that poor kidney function was linked specifically with cognition related to memory functions. Damage to one of these functions, episodic memory, which retrieves memories of time, place, associated emotions and other contextual knowledge, is often the earliest sign of Alzheimer's disease.
Sleepless nights may lead to the development of Alzheimer's disease over time, a study of mice suggests.
Rodents forced to stay awake showed a buildup in their brains of a protein associated with the development of Alzheimer's in humans, said lead study authoer Jae-Eun Kang. The research was published today in the journal Science.
Resarchers from the Memory and Cognition Center at University Hospitals Case Medical Center will begin testing an intriguing new approach to slowing down the progression of Alzheimer's Disease (AD) using Intravenous Immune Globulin (IGIV), also known as gammaglobulin. IGIV is traditionally used to treat primary immunodeficiency disorders, but is not currently approved for treating AD, which is one of the leading causes of dementia in the elderly.
Demographic ageing is a worldwide process that shows the successes of improved healthcare over the last century. Many are now living longer and healthier lives and so, the world population has a greater proportion of older people. We all agree that ageing brings some challenges as well. Many international meetings have touched on this issue and adopted statements, for instance, the Madrid International Plan of Action on Ageing from 2002.
For every excess pound piled on the body, the brain gets a little smaller.
That's the message from new research that found that elderly individuals who were obese or overweight had significantly less brain tissue than individuals of normal weight.
"The brains of obese people looked 16 years older than their healthy counterparts while [those of] overweight people looked 8 years older," said UCLA neuroscientist Paul Thompson, senior author of a study published online in Human Brain Mapping.
The world's population is graying, and as a result, nations around the globe are staring down a rising tide of people who will grapple with the ravages of Alzheimer's disease and other dementias. According to a new report from Alzheimer's Disease International, some 35.6 million people worldwide will have a form of dementia in 2010. That number is expected to nearly double every 20 years, reaching an estimated 65.7 million in 2030 and 115.4 million in 2050.